Matthieu Peyre1,2,3, Guillaume Gauchotte4, Marine Giry3, Sébastien Froehlich5, Johan Pallud6,7,8, Thomas Graillon9, Franck Bielle10, Dominique Cazals-Hatem11, Pascale Varlet7,8,12, Dominique Figarella-Branger13, Hugues Loiseau14, Michel Kalamarides1,2,3. 1. Department of Neurosurgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France. 2. Université Paris VI-Pierre et Marie Curie, Paris, France. 3. Inserm 1127 Unit-Institut du Cerveau et de la Moelle Epinière, Paris, France. 4. Department of Pathology, CHRU, INSERM U954, Nancy, France. 5. Department of Neurosurgery, Hôpital Lariboisière, APHP, Paris, France. 6. Department of Neurosurgery, Hôpital Sainte-Anne, Paris, France. 7. Paris Descartes University, Sorbonne Paris Cité, Paris, France. 8. IMA-BRAIN, Inserm, U894, Centre de Psychiatrie et Neurosciences, Paris, France. 9. Department of Neurosurgery, Hôpital la Timone, Marseille, France. 10. Department of Neuropathology, Hopital Pitié-Salpêtrière, APHP, Paris, France. 11. Department of Neuropathology, Hôpital Beaujon, Clichy, France. 12. Department of Neuropathology, Hopital Sainte-Anne, Paris, France. 13. Aix-Marseille Univ, APHM, INSERM, CRO2, La Timone Hospital, Department of Pathology and Neuropathology, Marseille, France. 14. Department of Neurosurgery, Hopital Pellegrin, Bordeaux, France.
Abstract
Background: Following recent studies underlining the differences between de novo and secondary anaplastic meningiomas and the prognostic value of telomerase reverse transcriptase (TERT) promoter mutation, we decided to conduct a multicenter retrospective study to address these questions and determine specific prognostic factors in each of these 2 anaplastic meningioma subgroups. Methods: Among the 68 meningioma cases initially selected, only 57 were confirmed as anaplastic meningiomas after centralized pathological review. TERT promoter mutation analysis was performed in all cases. Results: Median overall survival was 2.6 years and 5-year survival rate was 10%. This study confirmed the better prognosis of de novo anaplastic meningiomas (28 tumors) compared with secondary anaplastic meningiomas (29 tumors) (P = 0.02). In the "de novo" group, meningiomas diagnosed on histological anaplasia alone had a better prognosis than those in patients with a high number of mitoses with or without anaplasia (P = 0.01). In the "secondary" group, tumors demonstrate very heterogeneous clinical courses leading to malignant transformation, and time to first relapse as a low-grade tumor was a strong predictor of overall survival (P = 0.0007). TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02). The absence of TERT promoter methylation, although rare (3/33 cases), may be associated with prolonged overall survival (P = 0.02). Conclusion: This study highlights the different prognoses of de novo and secondary anaplastic meningiomas with specific prognostic factors in each subgroup. The analysis of TERT mutation and methylation could provide additional prognostic insights.
Background: Following recent studies underlining the differences between de novo and secondary anaplastic meningiomas and the prognostic value of telomerase reverse transcriptase (TERT) promoter mutation, we decided to conduct a multicenter retrospective study to address these questions and determine specific prognostic factors in each of these 2 anaplastic meningioma subgroups. Methods: Among the 68 meningioma cases initially selected, only 57 were confirmed as anaplastic meningiomas after centralized pathological review. TERT promoter mutation analysis was performed in all cases. Results: Median overall survival was 2.6 years and 5-year survival rate was 10%. This study confirmed the better prognosis of de novo anaplastic meningiomas (28 tumors) compared with secondary anaplastic meningiomas (29 tumors) (P = 0.02). In the "de novo" group, meningiomas diagnosed on histological anaplasia alone had a better prognosis than those in patients with a high number of mitoses with or without anaplasia (P = 0.01). In the "secondary" group, tumors demonstrate very heterogeneous clinical courses leading to malignant transformation, and time to first relapse as a low-grade tumor was a strong predictor of overall survival (P = 0.0007). TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02). The absence of TERT promoter methylation, although rare (3/33 cases), may be associated with prolonged overall survival (P = 0.02). Conclusion: This study highlights the different prognoses of de novo and secondary anaplastic meningiomas with specific prognostic factors in each subgroup. The analysis of TERT mutation and methylation could provide additional prognostic insights.
Authors: Felix Sahm; Daniel Schrimpf; Damian Stichel; David T W Jones; Thomas Hielscher; Sebastian Schefzyk; Konstantin Okonechnikov; Christian Koelsche; David E Reuss; David Capper; Dominik Sturm; Hans-Georg Wirsching; Anna Sophie Berghoff; Peter Baumgarten; Annekathrin Kratz; Kristin Huang; Annika K Wefers; Volker Hovestadt; Martin Sill; Hayley P Ellis; Kathreena M Kurian; Ali Fuat Okuducu; Christine Jungk; Katharina Drueschler; Matthias Schick; Melanie Bewerunge-Hudler; Christian Mawrin; Marcel Seiz-Rosenhagen; Ralf Ketter; Matthias Simon; Manfred Westphal; Katrin Lamszus; Albert Becker; Arend Koch; Jens Schittenhelm; Elisabeth J Rushing; V Peter Collins; Stefanie Brehmer; Lukas Chavez; Michael Platten; Daniel Hänggi; Andreas Unterberg; Werner Paulus; Wolfgang Wick; Stefan M Pfister; Michel Mittelbronn; Matthias Preusser; Christel Herold-Mende; Michael Weller; Andreas von Deimling Journal: Lancet Oncol Date: 2017-03-15 Impact factor: 41.316
Authors: Jennifer Moliterno; William P Cope; Emma D Vartanian; Anne S Reiner; Roselyn Kellen; Shahiba Q Ogilvie; Jason T Huse; Philip H Gutin Journal: J Neurosurg Date: 2015-04-10 Impact factor: 5.115
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Michael E Sughrue; Nader Sanai; Gopal Shangari; Andrew T Parsa; Mitchel S Berger; Michael W McDermott Journal: J Neurosurg Date: 2010-08 Impact factor: 5.115
Authors: Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee Journal: J Neuropathol Exp Neurol Date: 2002-03 Impact factor: 3.685
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling Journal: J Natl Cancer Inst Date: 2015-12-13 Impact factor: 13.506
Authors: Victor M Lu; Anshit Goyal; Adrian Lee; Mark Jentoft; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2018-12-01 Impact factor: 4.130
Authors: Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen Journal: Neurosurg Rev Date: 2019-03-13 Impact factor: 3.042
Authors: Francesco Maiuri; Giuseppe Mariniello; Marcello Barbato; Sergio Corvino; Elia Guadagno; Lorenzo Chiariotti; Marialaura Del Basso De Caro Journal: Neurosurg Rev Date: 2021-06-23 Impact factor: 3.042